These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27803008)

  • 1. The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
    Mangili G; Sigismondi C; Lorusso D; Cormio G; Candiani M; Scarfone G; Mascilini F; Gadducci A; Mosconi AM; Scollo P; Cassani C; Pignata S; Ferrandina G
    Ann Oncol; 2017 Feb; 28(2):333-338. PubMed ID: 27803008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study.
    Mangili G; Giorda G; Ferrandina G; Cormio G; Cassani C; Savarese A; Danese S; Carnelli M; Vasta FM; Perrone AM; Scarfone G; Pignata S; Legge F; Raspagliesi F; Taccagni G; Candiani M; Bogani G; Mascilini F; Bergamini A
    Int J Gynecol Cancer; 2021 Sep; 31(9):1242-1247. PubMed ID: 34035080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.
    Mangili G; Sigismondi C; Gadducci A; Cormio G; Scollo P; Tateo S; Ferrandina G; Greggi S; Candiani M; Lorusso D
    Int J Gynecol Cancer; 2011 Nov; 21(8):1414-21. PubMed ID: 21795985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
    Derquin F; Floquet A; Hardy-Bessard AC; Edeline J; Lotz JP; Alexandre J; Pautier P; Angeles MA; Delanoy N; Lefeuvre-Plesse C; Cancel M; Treilleux I; Augereau P; Lavoue V; Kalbacher E; Berton Rigaud D; Selle F; Nadeau C; Gantzer J; Joly F; Guillemet C; Pomel C; Favier L; Abdeddaim C; Venat-Bouvet L; Provansal M; Fabbro M; Kaminsky MC; Lortholary A; Lecuru F; Coquard IR; de La Motte Rouge T
    Gynecol Oncol; 2020 Sep; 158(3):666-672. PubMed ID: 32624235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery.
    Wang D; Zhu S; Jia C; Cao D; Wu M; Shen K; Yang J; Xiang Y
    Int J Gynecol Cancer; 2020 May; 30(5):664-669. PubMed ID: 32179695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance Only for High-risk FIGO Stage IA/IB Malignant Ovarian Germ Cell Tumors: Results From a National Cancer Database.
    Nasioudis D; Frey MK; Chapman-Davis E; Caputo TA; Holcomb KM
    Am J Clin Oncol; 2021 May; 44(5):195-199. PubMed ID: 33710136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
    Mangili G; Scarfone G; Gadducci A; Sigismondi C; Ferrandina G; Scibilia G; Viganò R; Tateo S; Villa A; Lorusso D
    Gynecol Oncol; 2010 Oct; 119(1):48-52. PubMed ID: 20599258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
    Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of the Complete Surgical Staging of Stage I Malignant Ovarian Germ Cell Tumors.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Ann Surg Oncol; 2016 Sep; 23(9):2982-7. PubMed ID: 27112586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
    Newton C; Murali K; Ahmad A; Hockings H; Graham R; Liberale V; Sarker SJ; Ledermann J; Berney DM; Shamash J; Banerjee S; Stoneham S; Lockley M
    Eur J Cancer; 2019 May; 113():19-27. PubMed ID: 30954883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis.
    Bergamini A; Sarwar N; Ferrandina G; Scarfone G; Short D; Aguiar X; Camnasio C; Kaur B; Savage PM; Cormio G; Lim A; Pignata S; Mangili G; Seckl MJ
    Eur J Cancer; 2020 Sep; 137():136-143. PubMed ID: 32763784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of lymphadenectomy on prognosis and survival of clinically apparent early-stage malignant ovarian germ cell tumors.
    Qin B; Xu W; Li Y
    Jpn J Clin Oncol; 2020 Mar; 50(3):282-287. PubMed ID: 31867612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MALIGNANT OVARIAN GERM CELL TUMORS AT A TERTIARY CARE SETTING IN PAKISTAN.
    Hannan A; Malik MA; Fasih S; Badar F; Siddiqui N
    J Ayub Med Coll Abbottabad; 2015; 27(3):624-7. PubMed ID: 26721024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes.
    Shim SH; Kim DY; Lee SW; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2013 Feb; 23(2):249-55. PubMed ID: 23318909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Surgery Alone and Surveillance Strategy in Young Women With Stage I Malignant Ovarian Germ Cell Tumors.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2016 Jun; 26(5):859-64. PubMed ID: 27101582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
    Palenzuela G; Martin E; Meunier A; Beuzeboc P; Laurence V; Orbach D; Frappaz D
    Ann Surg; 2008 Nov; 248(5):836-41. PubMed ID: 18948812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution.
    Hu T; Fang Y; Sun Q; Zhao H; Ma D; Zhu T; Wang C
    Surg Oncol; 2019 Dec; 31():8-13. PubMed ID: 31446304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study.
    Sigismondi C; Scollo P; Ferrandina G; Candiani M; Angioli R; Viganò R; Scarfone G; Mangili G
    Int J Gynecol Cancer; 2015 Feb; 25(2):203-7. PubMed ID: 25569816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant ovarian germ cell tumours: a trial of 36 cases].
    Gueye A; Narducci F; Baranzelli MC; Collinet P; Farine O; Fournier C; Vinatier D; Leblanc E
    Gynecol Obstet Fertil; 2007 May; 35(5):406-19. PubMed ID: 17350873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.